NCT02699502

Brief Summary

Metabolic therapy in patients with osteoporosis after hip fracture by cooperation orthopedic-rehabilitation-metabolic: Determination of drug treatment regardless of reaching the follow-up clinic

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
250

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2016

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 8, 2016

Completed
22 days until next milestone

Study Start

First participant enrolled

March 1, 2016

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 4, 2016

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2017

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2017

Completed
Last Updated

March 4, 2016

Status Verified

February 1, 2016

Enrollment Period

1 year

First QC Date

February 8, 2016

Last Update Submit

March 3, 2016

Conditions

Hip Fracture

Outcome Measures

Primary Outcomes (1)

  • The number of patients with hip fracture that will receive anti osteoporosis therapy without attending the metabolic clinic in comparison to previous results in the study mentioned above (No. Helsinki 0072-14-MMC)

    half a year

Secondary Outcomes (2)

  • Number of drugs that will be approved by the regulatory authorities

    half a year

  • Number of drugs that will be prescribed by family physicians

    half a year

Study Arms (1)

patients with osteoporotic hip fractures

EXPERIMENTAL

The intervention includes matching an appropriate drug to patients with hip fractures. All the relevant parameters regarding the patients with osteoporotic hip fractures will be reviewed (age, kidney function, previous treatment) and an appropriate anti osteoporosis medication will be determined. A recommendation regarding treatment will be sent to the local regulatory authorities, which will send the approved recommendation the the family physician.

Other: matching an appropriate drug therapy to patients with osteoporotic hip fractures

Interventions

matching an appropriate drug therapy to patients with osteoporotic hip fracturesOTHER

The process involves reviewing patients characteristics virtually and finding the right drug for them while they are still in the hospital. After matching an appropriate drug, getting it through regulatory authorities to the family physician

patients with osteoporotic hip fractures

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All patients were analyzed could Department of Orthopedics with a hip fracture

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Hip Fractures

Condition Hierarchy (Ancestors)

Femoral FracturesFractures, BoneWounds and InjuriesHip InjuriesLeg Injuries

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 8, 2016

First Posted

March 4, 2016

Study Start

March 1, 2016

Primary Completion

March 1, 2017

Study Completion

December 1, 2017

Last Updated

March 4, 2016

Record last verified: 2016-02

Data Sharing

IPD Sharing
Will not share